Digital & Computational Pathology - Executive Director of Translational Medicine, Midsize Biopharma

An executive director of translational medicine at a midsize biopharma discusses their current utilization and implementation of digital pathology technologies. They currently utilize digital pathology across basic, translational, and clinical research. This stakeholder also discusses their satisfaction with various vendors, including uncertainty and cost. This stakeholder also highlighted the unique value derived from utilizing 3DHISTECH, Siemens Healthineers, Aiforia, Proscia, PathAI, Flagship, PreciseDX, and Deciphex. They mention that there are multiple pain points preventing greater adoption of digital pathology infrastructure, such as regulatory uncertainty and cost. This stakeholder also highlighted the unique value derived from utilizing digital pathology, such as increased throughput, objectivity, and reproducibility. Finally, they discuss market trends, including the increasing use of immunohistochemistry and the potential for clinical diagnostics to increase in the future, particularly in the oncology space.

‍